TPO Antibodies Test: When to Order It, What Results Mean, and Why Women Need to Know

What TPO Antibodies Actually Are

Thyroid peroxidase is an enzyme your thyroid gland needs to make thyroid hormone. Your immune system sometimes misidentifies it as a foreign threat and produces antibodies against it. These are TPO antibodies, also called anti-TPO or anti-thyroid peroxidase antibodies.

A detectable TPO antibody level is the single most reliable blood marker for Hashimoto's thyroiditis, the autoimmune condition responsible for the majority of hypothyroidism cases in iodine-sufficient countries. The antibodies themselves may not damage your thyroid directly. They are a sign that immune-mediated inflammation is occurring, and that inflammation progressively destroys thyroid tissue over years or decades.

You can have elevated TPO antibodies with a completely normal TSH. That is called euthyroid Hashimoto's. You can also have elevated TPO antibodies alongside an already-elevated TSH, meaning overt or subclinical hypothyroidism has set in. The antibody result and the TSH result together tell a more complete story than either test alone.

Why This Test Is Particularly Relevant for Women

Hashimoto's thyroiditis affects women at a rate 5 to 10 times higher than men, and peak incidence falls squarely across the reproductive years and perimenopause, the same windows when women are most likely to attribute fatigue, weight gain, brain fog, or mood changes to stress, hormones, or aging. That overlap is where diagnoses get missed.

The Endocrine Society estimates that approximately 5% of women of reproductive age carry elevated TPO antibodies with a normal TSH. In peri- and postmenopausal women, prevalence climbs higher because cumulative immune dysregulation increases with age and hormonal transition.

When You Should Order This Test

Ordering TPO antibodies is not a blanket screening recommendation for all women. The American Thyroid Association (ATA) and AACE guidelines define specific clinical indications. Here is where the evidence supports testing.

Symptomatic Thyroid Disease

Order TPO antibodies alongside TSH when a woman presents with:

• Persistent fatigue, cold intolerance, constipation, or dry skin unexplained by other causes
• Diffuse goiter or a nodular thyroid on exam
• Unexplained weight gain or difficulty losing weight despite normal caloric intake
• Hair thinning or diffuse hair loss, including female-pattern hair loss
• Depression or anxiety that is not responding well to psychiatric treatment
• Irregular menstrual cycles without a clear gynecologic cause

A TSH alone misses the autoimmune component. If TSH is normal but symptoms persist, TPO antibodies can reveal subclinical Hashimoto's that will eventually progress.

Infertility and Recurrent Pregnancy Loss

This is one of the most clinically significant indications for women. Elevated TPO antibodies are found in approximately 10% of women presenting with unexplained infertility and in a disproportionate share of women with recurrent miscarriage. A large 2011 meta-analysis published in Fertility and Sterility confirmed that TPO-antibody-positive euthyroid women face a significantly elevated miscarriage risk compared to antibody-negative controls.

ASRM and ACOG both recognize thyroid autoimmunity as a factor in recurrent pregnancy loss evaluations. If you have had two or more miscarriages, a TPO antibody test belongs in your workup even when your TSH looks normal.

Early Pregnancy

ACOG Practice Bulletin No. 223 recommends targeted, not universal, thyroid screening in pregnancy. TPO antibodies specifically should be ordered in early pregnancy (ideally before 10 weeks) when a woman has:

• A personal history of thyroid disease or thyroid surgery
• A family history of autoimmune thyroid disease
• A prior pregnancy complicated by postpartum thyroiditis or miscarriage
• Type 1 diabetes or another autoimmune condition
• Symptoms of hypothyroidism at any point in pregnancy

Why does this matter in pregnancy? TSH rises in TPO-positive pregnant women faster than in antibody-negative women, and the fetal brain depends on adequate maternal thyroid hormone through at least the second trimester. The downstream risk for the baby, not just the mother, is the reason early identification matters.

Postpartum Thyroiditis Evaluation

Postpartum thyroiditis affects 5 to 10% of all postpartum women, and roughly 80% of those women are TPO-antibody positive before or during pregnancy. If you or your provider suspect postpartum thyroiditis because of new fatigue, palpitations, mood swings, or weight changes in the first year after delivery, TPO antibodies plus TSH and free T4 are the right initial panel.

Many cases of postpartum thyroiditis are misattributed to postpartum depression or "new mom exhaustion." A missed thyroid diagnosis at this stage can mean months of unnecessary suffering.

Perimenopause and Menopause

Perimenopause is a window of significant immune dysregulation. Estrogen has direct immunomodulatory effects, and as estrogen levels become erratic and then fall in perimenopause, autoimmune conditions including Hashimoto's can accelerate or newly declare themselves.

Here is a clinical framework specific to WomanRx readers: if you are in perimenopause (irregular cycles, vasomotor symptoms, age 40 to 55) and your TSH is above 2.5 mIU/L on two separate draws, or you have symptoms that do not fully respond to hormone therapy, check TPO antibodies. A positive result changes the monitoring plan: TSH should be rechecked every six months rather than annually, and you and your clinician should agree on a TSH threshold for starting levothyroxine. The Menopause Society does not set a universal treatment threshold for subclinical hypothyroidism in menopause, but consensus guidance from the ATA notes that women with TSH above 10 mIU/L and positive TPO antibodies have a higher rate of progression to overt hypothyroidism and are generally candidates for treatment.

PCOS and Other Autoimmune Conditions

Women with PCOS have a 3-fold higher prevalence of Hashimoto's thyroiditis compared to controls without PCOS, based on a 2013 review in the European Journal of Endocrinology. The shared substrate of insulin resistance and chronic low-grade inflammation may partially explain this association. If you have a confirmed PCOS diagnosis, TPO antibodies are a reasonable add-on during your annual thyroid function check.

Other conditions that raise the pre-test probability enough to justify TPO antibody testing include Type 1 diabetes, rheumatoid arthritis, lupus, celiac disease, and vitiligo.

Understanding Your TPO Antibody Result

Normal TPO Antibodies Range

Most commercial laboratory assays set the upper limit of normal between 9 and 35 IU/mL. Quest Diagnostics and LabCorp, the two largest reference labs in the United States, both use a cutoff of <35 IU/mL for a negative result, though the exact cutoff varies by assay method. Always interpret your result against the reference range printed on your specific lab report, because different immunoassay platforms are not interchangeable.

A result just above the cutoff (35 to 100 IU/mL) may be weakly positive. Results above 500 IU/mL are strongly positive and are nearly always associated with Hashimoto's. The absolute number does not predict how fast your thyroid will fail. Serial TSH monitoring matters more than serial TPO antibody levels once a positive result is established.

What a High TPO Antibody Level Means

A high TPO antibody level means your immune system is actively producing antibodies against your thyroid gland. By itself, it does not mean you need medication. It means:

• You have autoimmune thyroid disease, most likely Hashimoto's thyroiditis
• Your thyroid function should be monitored at regular intervals (every 6 to 12 months with TSH, or more frequently in pregnancy)
• You are at increased risk for developing overt hypothyroidism over time
• Specific life situations (pregnancy, postpartum, perimenopause) warrant closer monitoring because your thyroid reserve may be reduced

The Endocrine Society's 2012 Clinical Practice Guideline on thyroid dysfunction in pregnancy states that euthyroid women who are TPO-antibody positive should have TSH assessed at diagnosis of pregnancy and again at 26 to 28 weeks gestation, given the increased risk of hypothyroidism developing during pregnancy.

Graves' disease, another autoimmune thyroid condition causing hyperthyroidism, can also be associated with mildly elevated TPO antibodies. But Graves' disease is more specifically marked by TSH receptor antibodies (TRAb) or thyroid-stimulating immunoglobulins (TSI). If your TSH is low and your free T4 is high, your clinician will likely order those additional markers rather than relying on TPO antibodies alone.

What a Low or Negative TPO Antibody Level Means

A negative TPO antibody result is reassuring. It makes Hashimoto's thyroiditis much less likely as a cause of thyroid symptoms. However, a negative result does not rule out all thyroid conditions.

A small percentage of people with biopsy-confirmed Hashimoto's are persistently seronegative (antibody-negative). If your symptoms are strong and your TSH is elevated, your clinician may still pursue thyroid ultrasound even with a negative TPO antibody test.

TPO antibodies can also be transiently negative during immune suppression, during pregnancy in some women, or with certain medications. Context always matters.

Sex-Specific Physiology: How Hormones and Life Stage Change Everything

During the Reproductive Years

Estrogen has a net immune-stimulating effect. Women in their reproductive years maintain higher baseline immune surveillance than men the same age, which is part of why autoimmune diseases broadly are more common in women. Roughly 75% of all autoimmune disease patients are female, and the thyroid is one of the most autoimmune-susceptible organs.

Thyroid hormone requirements rise by approximately 30 to 50% during pregnancy because the feto-placental unit requires maternal T4, renal clearance of iodine increases, and hCG in the first trimester stimulates TSH receptor activity in ways that complicate interpretation. If you are TPO-antibody positive and become pregnant, your levothyroxine dose may need to increase as early as week 4 to 6, before your first obstetric appointment.

Pregnancy and Lactation Safety Considerations

TPO antibodies are a lab marker, not a medication, so there is no direct drug safety concern with the test itself. The clinical relevance in pregnancy and lactation concerns what happens after a positive result.

In pregnancy: Untreated overt hypothyroidism in pregnancy is associated with increased risk of preterm birth, placental abruption, low birthweight, and impaired fetal neurodevelopment. The treatment is levothyroxine, which is safe in pregnancy and during breastfeeding. Levothyroxine crosses the placenta in minimal amounts and is classified as FDA Pregnancy Category A based on long clinical experience.

Subclinical hypothyroidism in pregnancy: The TABLET trial (2019), a large UK randomized controlled trial, found that levothyroxine treatment of euthyroid TPO-antibody-positive women did not reduce miscarriage rates compared to placebo. This was a significant and somewhat unexpected finding that has changed how some clinicians approach TPO-positive euthyroid women before and early in pregnancy. However, the trial did not enroll women with subclinical hypothyroidism (elevated TSH), and ACOG's guidance remains that women with elevated TSH plus positive TPO antibodies should be treated regardless of TABLET's findings.

Contraception note: This is not a teratogenic medication context. However, women who are TPO-antibody positive and planning pregnancy should establish a relationship with their prescriber for thyroid monitoring before conception, so that TSH can be optimized to below 2.5 mIU/L before trying to conceive. That is a proactive step, not a reason to avoid pregnancy.

During breastfeeding: Postpartum thyroiditis typically peaks at 3 to 6 months postpartum. If you are breastfeeding and develop hyperthyroid or hypothyroid symptoms, TPO antibodies plus TSH and free T4 will clarify the picture. Levothyroxine is considered compatible with breastfeeding by the American Academy of Pediatrics. Methimazole (used for the hyperthyroid phase of postpartum thyroiditis) is also compatible with breastfeeding at doses below 20 to 30 mg/day according to LactMed.

Perimenopause and Post-Menopause

As estrogen declines, immune regulation shifts. Some women who had subclinical Hashimoto's during their reproductive years see a faster progression to hypothyroidism during perimenopause. Others develop newly elevated TPO antibodies for the first time after menopause.

The symptom overlap between hypothyroidism and perimenopause is substantial: fatigue, weight gain, mood disturbance, cognitive changes, disrupted sleep. A TSH and TPO antibody panel should be part of any thorough perimenopause evaluation when symptoms are present. Starting menopausal hormone therapy (MHT) in a woman with undiagnosed hypothyroidism will not fully resolve her symptoms.

One additional wrinkle: oral estrogen increases thyroxine-binding globulin (TBG), which means women on oral MHT who are also on levothyroxine may need a higher levothyroxine dose. This does not apply to transdermal estrogen, which does not significantly alter TBG. If you start or change MHT and your symptoms return, ask your clinician to recheck your TSH.

How to Lower TPO Antibodies

This question is common and the honest answer is: no intervention has been proven in high-quality trials to reliably reduce TPO antibody levels in a way that changes clinical outcomes.

Several strategies have evidence of varying quality:

Selenium: A 2016 Cochrane-style meta-analysis of selenium supplementation in autoimmune thyroiditis found that selenium (typically 200 mcg/day of selenomethionine) reduced TPO antibody titers significantly compared to placebo over 3 to 12 months. Thyroid volume and well-being also improved in some trials. The ATA has not formally endorsed selenium as standard treatment, noting the evidence base remains small and the clinical significance of antibody reduction is unclear. Selenium is not risk-free at high doses; doses above 400 mcg/day are associated with selenosis.

Gluten-free diet: Some women with Hashimoto's and concurrent celiac disease see TPO antibody reductions on a strict gluten-free diet. In women without celiac disease, the evidence does not support a gluten-free diet as an antibody-lowering intervention. Testing for celiac (tissue transglutaminase IgA) is reasonable in any TPO-positive woman who also has gastrointestinal symptoms or iron-deficiency anemia without a clear cause.

Vitamin D: Low vitamin D is associated with higher TPO antibody titers in observational data, but randomized trials of vitamin D supplementation have not consistently shown that correcting deficiency lowers antibodies significantly. Correcting frank vitamin D deficiency (<20 ng/mL) is warranted for bone and immune health regardless of TPO status.

Levothyroxine itself: In women with subclinical or overt hypothyroidism plus positive TPO antibodies, treating with levothyroxine and normalizing TSH may modestly reduce antibody titers over time, though this is not the primary reason to prescribe it. The primary reason is to normalize thyroid function.

The evidence gap here is real. Most trials of dietary or supplement interventions in Hashimoto's enrolled small numbers, lacked strong controls, and were not powered to assess clinical outcomes like pregnancy loss or cardiovascular risk. Be skeptical of any protocol promising to "reverse" or "heal" Hashimoto's through diet alone.

What Cannot Raise TPO Antibodies

The framing of "how to raise TPO antibodies" occasionally appears in searches, sometimes from women who have been told their antibodies are too low. To be direct: there is no clinical scenario in which a practitioner would want to raise TPO antibody levels. Low or negative TPO antibodies are a favorable finding. The goal in treating Hashimoto's is to manage thyroid function, not to modulate antibody levels upward. If someone has suggested you need higher TPO antibodies, that recommendation is not supported by any current endocrine guideline.

Who This Test Is Right For and Who Can Wait

Order TPO antibodies if you are:

• A woman with persistent fatigue, hair loss, weight changes, or menstrual irregularities and a TSH above 2.5 mIU/L
• Planning pregnancy or in the first trimester with any thyroid history or autoimmune condition
• Experiencing recurrent miscarriage or unexplained infertility
• Postpartum with new or worsening mood, fatigue, or palpitations
• In perimenopause with an abnormal TSH or symptoms not fully explained by estrogen decline
• Diagnosed with PCOS, Type 1 diabetes, celiac disease, or another autoimmune condition

You can likely defer TPO antibodies if you are:

• Asymptomatic with a normal TSH and no personal or family history of thyroid disease
• Already on stable levothyroxine with a known Hashimoto's diagnosis (the antibody level will not change your current management)
• Seeking general wellness screening without a clinical indication (current USPSTF guidance does not recommend universal thyroid screening in asymptomatic adults)

The USPSTF 2015 statement found insufficient evidence to assess the benefits and harms of screening for thyroid dysfunction in nonpregnant, asymptomatic adults. That applies to TPO antibody testing as well. "Ordering everything" is not more thorough care; it generates anxiety and false positives without improving outcomes in low-risk women.

Monitoring After a Positive Result

Once you know your TPO antibodies are elevated, the antibody number itself rarely needs to be retested. What needs monitoring is your thyroid function:

• TSH every 6 to 12 months if your TSH is currently normal
• TSH plus free T4 in early pregnancy and again at 26 to 28 weeks if you are pregnant
• TSH at 3 and 6 months postpartum if you were TPO-antibody positive during pregnancy
• TSH 4 to 8 weeks after any change in levothyroxine dose or after starting oral estrogen therapy

The Endocrine Society's 2012 guideline on management of thyroid dysfunction during pregnancy and postpartum specifies that TPO-antibody-positive euthyroid women who do not need levothyroxine during pregnancy should still have TSH monitored at each trimester because approximately 16 to 20% will develop gestational hypothyroidism.

Ask your clinician: what TSH level would prompt treatment in my specific situation, given my TPO antibody status, my age, and my reproductive goals? That conversation is more useful than any single lab value.